Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and insights that, taken together, suggest treatment strategies that offer the ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...